|
39 Companies |
|
49 Products |
|
49 Products |
|
46 Mechanisms of Action |
|
0 Trials |
|
259 News |
|
| «123456 |
- | Vynfinit (vintafolide) / Novartis
Trial completion: Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03) (clinicaltrials.gov) - Mar 4, 2012
P2, N=43, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed
- erlotinib / Generic mfg., capecitabine / Generic mfg.
Trial completion, Combination therapy, Metastases: A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung (clinicaltrials.gov) - Feb 27, 2012
P2, N=62, Completed, Sponsor: Sun Yat-sen University
Active, not recruiting --> Completed Recruiting --> Completed
- Enrollment change, Metastases: Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages (clinicaltrials.gov) - Jan 10, 2012
P2, N=6, Completed, Sponsor: Roswell Park Cancer Institute
Recruiting --> Completed N=20 --> 6
- | Gilotrif (afatinib) / Boehringer Ingelheim
Trial completion: A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR] (clinicaltrials.gov) - Dec 15, 2011
P2, N=43, Completed, Sponsor: Boehringer Ingelheim
N=20 --> 6 Active, not recruiting --> Completed
- ||||| Gilotrif (afatinib) / Boehringer Ingelheim
Enrollment closed: LUX-Lung 6: BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Dec 13, 2011
P3, N=364, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Enrollment closed, Gene Expression Profile: Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer (clinicaltrials.gov) - Dec 1, 2011
P3, N=1620, Active, not recruiting, Sponsor: Cancer and Leukemia Group B
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- gefitinib / Generic mfg., docetaxel / Generic mfg.
Trial completion: Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 30, 2011
P1, N=45, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Trial completion, Surgery: Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Oct 19, 2011
P3, N=1200, Completed, Sponsor: American College of Surgeons
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial completion, Combination therapy, Metastases: Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy (clinicaltrials.gov) - Oct 18, 2011
P2, N=46, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Enrollment change: A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma (clinicaltrials.gov) - Sep 28, 2011
P1, N=2, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=20 --> 2
- Avastin (bevacizumab) / Roche
Trial completion: A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma (clinicaltrials.gov) - Sep 28, 2011
P1, N=2, Completed, Sponsor: National Cancer Institute (NCI)
N=20 --> 2 Recruiting --> Completed
- Vesanoid (tretinoin) / Roche
Enrollment change, Metastases: Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer (clinicaltrials.gov) - Sep 26, 2011
P2, N=24, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Completed N=48 --> 24
- temozolomide / Generic mfg.
Enrollment change: Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 25, 2011
P2, N=26, Completed, Sponsor: Eastern Cooperative Oncology Group
N=48 --> 24 N=53 --> 26
- temozolomide / Generic mfg.
Trial completion: Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 25, 2011
P2, N=26, Completed, Sponsor: Eastern Cooperative Oncology Group
N=53 --> 26 Active, not recruiting --> Completed
- gefitinib / Generic mfg.
Trial initiation date: ARPEGE: Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis (clinicaltrials.gov) - Sep 11, 2011
P=N/A, N=60, Recruiting, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed Initiation date: May 2011 --> Mar 2012
- gefitinib / Generic mfg.
Enrollment open: ARPEGE: Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis (clinicaltrials.gov) - Sep 11, 2011
P=N/A, N=60, Recruiting, Sponsor: Assistance Publique - H
Initiation date: May 2011 --> Mar 2012 Active, not recruiting --> Recruiting
- Clinical: Study of Proteins in Tumor Samples From Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 10, 2011
P=N/A, N=261, Not yet recruiting, Sponsor: Cancer and Leukemia Group B
- |||| Avastin (bevacizumab) / Roche
Trial completion, Metastases: Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 9, 2011
P2, N=60, Completed, Sponsor: North Central Cancer Treatment Group
Active, not recruiting --> Recruiting Active, not recruiting --> Completed